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Purpose: Follicular lymphoma (FL) is an indolent non-Hodgkin’s lymphoma that is highly sensitive to radiotherapy (RT). However, 
the effectiveness of RT has not been well established. We reviewed our experiences to assess the role of RT for FL and analyze 
treatment results.
Materials and Methods: Retrospective analysis was done on 29 patients who received first RT between January 2003 and 
August 2013. Of 23 early stage (stage I, II) patients, 16 received RT alone, four received chemotherapy followed by RT, two received 
RT postoperatively, and one received salvage RT for relapse after resection. Six advanced-stage (stage III, IV) patients received 
RT after chemotherapy: two received consolidation RT, three received salvage RT for residual lesions, and one received RT for 
progressive sites. Median RT dose was 30.6 Gy (range, 21.6 to 48.6 Gy). Median follow-up duration was 62 months (range, 6 to 141 
months).
Results: All patients showed complete response in the radiation field. Eight outfield relapses were reported. Seven patients 
received salvage treatment (three chemotherapy, four RT). Four patients showed excellent responses, especially to RT. Estimated 
5-year and 10-year relapse-free survivals were 72% and 60%. In the RT-alone group, 5-year relapse-free survival was 74.5%. All 
advanced-stage patients were disease-free with 100% 5-year overall survival. Disease-specific death was noted in only one patient; 
four others died of other unrelated causes. No significant toxicity was reported.
Conclusion: RT resulted in excellent treatment outcomes for all FL stages when used as a primary treatment modality for early 
stage or salvage-treatment modality for advanced-stage disease.
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Introduction
Follicular lymphoma (FL) is a tumor of follicle center B cells 
(centrocytes and centroblasts) and has a follicular (nodular) 
pattern that is morphologically similar to normal germinal 
centers. FL is approximately 20% of all newly diagnosed 
lymphoma cases and is reported to be the second most 
common subtype of non-Hodgkin lymphoma in the United 
States. FL is relatively rare in Korea; at 2.9%, it is the sixth 
most common non-Hodgkin lymphoma subtype in Korea [1]. 
For early stage FLs, the current treatment options in patients 
with stage I or contiguous stage II FL include observation, 
radiotherapy (RT), chemotherapy, and combined treatment 
modalities of chemotherapy plus RT. For advanced-stage FLs, 
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treatment is required in symptomatic or bulky tumors, and 
chemotherapy including rituximab is usually recommended.
Localized and early stage FLs (Ann Arbor stage I and 
II) are 22%–33% of all FL cases [2]. RT alone is the well-
recognized, preferred treatment of choice in several 
international guidelines [3,4]. FL has long been recognized as 
more radiosensitive than other lymphoma subtypes and the 
efficacy of RT is observed even at low radiation doses. Several 
studies reviewed the long-term outcomes of RT alone and 
reported relapse-free survival (RFS) of 50% at 10 years and 
approximately 40% at 15 years; overall survival (OS) rates were 
60%–80% and 35%–45%, respectively [5]. Thus, RT is regarded 
as a curative treatment modality for a significant number of 
patients with early stage FL.
For advanced-stage FL, a watch-and-wait policy is the 
preferred treatment of choice for patients without symptoms 
and with low tumor burden. Because of the indolent course 
of FL and the lack of life-prolonging or curative therapy, this 
strategy was established in the 1990s. A few prospective 
randomized studies demonstrated that systemic therapy 
could be safely delayed until treatment is necessary without 
negatively influencing patient outcomes [6,7]. For patients 
with a high tumor volume or symptoms requiring treatment, 
a combination of rituximab and chemotherapy is the standard 
treatment, with higher response and survival rates than 
chemotherapy without rituximab [8-12]. RT could be a good 
alternative approach in these patients. However, because of the 
lack of data on RT as a first-line treatment for advanced-stage 
FL, RT is currently recommended only for palliative treatment 
of locally symptomatic disease or second-line therapy for 
relapsed or refractory disease. Several studies have found 
RT to be an excellent palliative modality that provides long-
term local control and clinical benefits even for advanced-
stage FL. Even very small doses of 4 Gy could have benefits for 
patients with advanced, relapsed, or refractory stage FL [13,14]. 
With the extreme radiosensitivity of FL, RT for advanced-
stage FL should also be established and is expected to be more 
extensively used than under currently recommended use. No 
studies have investigated RT outcomes in advanced-stage FL 
patients, especially in Korea.
In Korea, most radiation oncologists do not have opportunity 
to experience treating FL because of the low incidence and 
low RT referral rates. Therefore, we retrospectively reviewed RT 
experience at our institution with the aim of analyzing overall 
treatment results and defining the role of RT for FL treatment.
Materials and Methods
1. Patients
A total of 34 patients with FL who were diagnosed and 
received first RT between September 2000 and August 
2013 at Severance Hospital were identified. Two patients 
with uncertain pathology and three with a short follow-up 
period were excluded. Therefore, a total of 29 patients were 
included in the current study. All patients were pathologically 
diagnosed with FL by biopsy or surgical excision. Ann Arbor 
stage I and II FL was classified as early stage, and Ann Arbor 
stage III and IV was classified as advanced-stage. Patients were 
staged according to physical examination, imaging studies, 
blood chemistry, and bone marrow biopsy. Imaging studies 
included computed tomography (CT) scan or positron emission 
tomography (PET)-CT. Nine patients were diagnosed using CT 
scan only (June 2000 to January 2003) and 20 patients were 
diagnosed using both CT and PET-CT (June 2003 to June 2013). 
Complete blood counts and lactate dehydrogenase (LDH) levels 
were determined. Revised Follicular Lymphoma International 
Prognostic Index 2 (FLIPI 2) scores were calculated based on 
individual parameters (low risk group, 0–1; intermediate risk 
group, 2; high risk group, 3–5) [15]. 
The early stage group had 23 patients (Ann Arbor stage I, 
17; stage II, 6); the advanced-stage group had 6 (Ann Arbor 
stage IIIA, 2; stage IVA, 4). Median age at diagnosis was 59 
years (range, 16 to 83 years). Median follow-up duration was 
62 months (range, 9 to 155 months) after initial diagnosis. 
Patient and tumor characteristics are in Table 1.
2. Treatment
Of the 23 early stage patients, 16 received RT alone, four 
received chemotherapy followed by RT, two received RT 
postoperatively, and one received salvage RT for relapse after 
resection. All six advanced-stage patients received RT after 
chemotherapy: two received consolidation RT, three received 
salvage RT for residual lesions, and one received RT for 
progressive sites (Fig. 1).
Treatment details of early stage patients were as follows. 
In the RT-alone group (n = 16), 4 patients received extended-
field RT (EFRT) (three as supradiaphragmatic extended-field 
RT, mantle field with or without Waldeyer’s ring, and one as 
subdiaphragmatic extended-field RT [inverted Y field]) and 
12 received involved-filed RT (IFRT). The median total RT 
dose was 30.6 Gy (range, 24 to 45 Gy) as 1.8 Gy or 2.0 Gy per 
fraction. In the RT-after-chemotherapy group (n = 4), three 
patients refused additional chemotherapy after receiving 
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1–2 chemotherapy cycles and one received RT for suspected 
residual disease after 6 chemotherapy cycles. In the RT-after-
surgery group (n = 2), all patients were initially diagnosed with 
suspicious parotid gland masses and first received surgical 
excision with a curative or diagnostic aim. After pathological 
examination, additional RT was performed postoperatively to 
cover microscopically suspicious areas around the operation 
site (All patients were treated with IFRT with 21.6 Gy in 1.8 Gy-
fractions or 40 Gy in 2 Gy-fractions). In the salvage-RT group (n 
= 1), the patient was diagnosed with a suspicious lung nodule 
in the left lower lobe. After surgical excision, pathological 
diagnosis confirmed FL. After 2 years of follow-up without 
adjuvant treatment, a relapse in the mediastinal lymph node 
area was discovered and 30 Gy of mantle field RT including 
the mediastinal lymph node area was selected as the salvage 
treatment.
Treatment details for advanced-stage patients were as 
follows. In the salvage-RT group, three patients received RT for 
residual lesions after chemotherapy completion and one patient 
received RT for progressive disease sites. Almost all patients 
received 30.6 to 35 Gy of extended-field RT (two with additional 
whole-abdomen RT of 24 Gy), except for a single patient who 
received IFRT 30.6 Gy. Of the consolidation-RT patients, one 
was initially diagnosed with FL involving the left neck level V 
lymph node and left proximal humerus. This patient received 
6 cycles of rituximab plus cyclophosphamide, doxorubicin, 
vincristine, and prednisone (R-CHOP) chemotherapy; complete 
remission (CR) at disease sites was noted. As a consolidation 
aim, an additional 25.2 Gy IFRT was administered to the left 
neck and humerus. Another patient was initially diagnosed 
with FL involving the neck, axilla, para-aortic, and inguinal 
lymph node areas; this patient received with 6 cycles of CAVOP 
(cyclophosphamide, adriamycin, vincristine, VP-16, prednisone 
chemotherapy). After CR, an additional 24 Gy of extended-field 
RT (mantle field) was administered.
3. Response evaluation and statistical analysis
Response to therapy was evaluated within 6–12 weeks after RT 
and careful long-term follow-up evaluations were maintained. 
Regular posttreatment monitoring was based on laboratory 
tests and clinical or radiological examination if appropriate 
of all peripheral lymph node sites. Follow-up imaging studies 
were at least a CT scan of the involved region with PET-
CT scans used more recently. CR was defined as complete 
disappearance of all detectable evidence of disease. Responses 
after the initial treatment schedule were evaluated in all 
patients and relapse or progression, defined as appearance of 
a new lesion or increase in initial tumor size, was evaluated 
with follow-up images. Toxicity was graded using the Common 
Terminology Criteria for Adverse Events (CTCAE) ver. 4.0.
OS was estimated from initial diagnosis to last follow-up or 
date of death from any cause. RFS was measured from initial 
diagnosis to date of relapse/progression or to last follow-
Table 1. Patient characteristics (n = 29)
Variable No. (%)
Age (yr), median (range)
   ≥60
   <60
Sex 
   Male
   Female
No. of involved nodal areas
   >4
   ≤4
BM involvement
   Yes
   No 
Anemiaa)
   Yes
   No 
LN >6 cm
   Yes
   No
LDH elevationb)
   Yes
   No 
   No information
β2-microglobulin elevationc)
   Yes
   No
   No information
Ann Arbor stage
   IA
   IEA
   IB
   IIA
   IIEA
   IIIA
   IVA
FLIPI2 group
   Low risk
   Intermediate risk
   High risk
   Unevaluable
58 (16–83)
14 (48.3)
15 (51.7)
 
11 (37.9)
18 (62.1)
 
7 (24.1)
22 (75.9)
 
2 (93.1)
27 (6.9)
 
6 (79.3)
23 (20.7)
 
2 (93.1)
27 (6.9)
 
15 (51.7)
13 (44.8)
1 (3.5)
 
7 (24.1)
17 (58.6)
5 (17.3)
 
13 (44.8)
3 (10.3)
1 (3.5)
5 (17.2)
1 (3.5)
2 (6.9)
4 (13.8)
 
15 (51.7)
7 (24.1)
4 (13.8)
3 (10.4)
BM, bone marrow; LN, lymph node; LDH, lactate dehydrogenase; 
FLIPI2, Follicular Lymphoma International Prognostic Index 2.
a)Anemia, <13 g/dL (male) or 12 g/dL (female). b)LDH elevation, 
>247 IU/L. c)β2-microglobulin elevation, >2.74 mg/L.
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up date for patients who did not experience these events. OS 
and RFS were calculated using the Kaplan-Meier method. The 
statistical significance of differences in Kaplan-Meier estimates 
was assessed using the log-rank test. All point estimates were 
accompanied by 95% confidence interval. A p < 0.05 was 
considered statistically significant. Statistical analysis was 
performed using IBM SPSS ver. 20 (IBM, Armonk, NY, USA).
Results
1. Early stage patients
After RT, all patients showed CR in the radiation field. In the 
RT-alone group (n = 16), all patients (100%) showed CR in 
radiation field. There is no infield relapse, and four patients (one 
with mantle field, three with IFRT) showed outfield relapse 
(median RFS from initial diagnosis, 34 months; range, 11 to 
Early stage
(n = 23)
RT alone
n = 16 (70%)
RT-after-
chemotherapy group
n = 4 (17%)
RT-after-
surgery group
n = 2 (9%)
Salvage RT for
relapse after
resection
n = 1 (4%)
CR
CR
CR
CR
n = 4
Out-field relapse
n = 2
Out-field relapse
n = 10
Alive without disease
n = 2
Died of
disease-unrelated cause
n = 2
Alive without disease
n = 2
Alive without disease
n = 3
Alive without disease
n = 2
Alive without disease
n = 1
Alive without disease
n = 1
Died of
disease-unrelated cause
n = 3
Alive without disease
n = 1
Died of
disease-unrelated cause
n = 1 Died of disease
n = 1 Alive with disease
A
CR
CR
CR
n = 2
Out-field relapse
Advanced stage
(n = 6)
Salvage RT for
residual lesion
after
chemotherapy
n = 3 (50%)
Consolidation
RT after
chemotherapy
n = 2 (33%)
Salvage RT for
progressive
lesion after
chemotherapy
n = 1 (17%)
B
Fig. 1. Treatment flowchart of 29 
patients with follicular lymphoma. 
RT, radiotherapy; CR, complete 
remission.
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84 months). Of these patients, two were treated with salvage 
IFRT at relapse sites and two received salvage chemotherapy. 
Three patients (19%) died, and all deaths were unrelated to FL. 
Two patients, aged 75 and 90 years, died of other underlying 
medical diseases and one died of a second malignancy 122 
months after FL diagnosis.
In the RT-after-chemotherapy group (n = 4), all patients 
(100%) showed CR in radiation field. Two patients showed 
outfield relapse at 17 and 43 months after RT. One initially 
responded well to salvage treatment with several cycles of 
chemotherapy, but infield disease relapse in the inguinal and 
pelvic lymph node area continued. This patient was enrolled 
in a clinical trial and was alive with disease and receiving 
chemotherapy. The other patient did not respond to salvage 
treatment despite several cycles of RT and chemotherapy, 
and died of disease 2 years after systemic relapse. All patients 
except this patient (75%) are alive until last follow-up date.
Both RT-after-surgery group and salvage RT for relapse 
after resection group also showed 100% of CR in radiation 
field. There was only one death in salvage-RT group, which 
was unrelated to FL (advanced gastric cancer). There was no 
treatment-related toxicity after RT in all patients of early stage 
group to the last follow-up date.
2. Advanced-stage patients 
All six advanced-stage patients received RT after chemotherapy. 
Two received consolidation RT, three received salvage RT for 
residual lesions, and one received RT for progressive sites. After 
RT, all patients showed CR in the radiation field.
In the salvage-RT group, all patients (100%) showed CR 
in radiation field, and there was no disease-related death. 
Two of a total of four patients showed relapses at 22 and 
26 months after RT. One showed suspected outfield relapse 
in the left para-aortic lymph node at 29 months after initial 
diagnosis. This patient was alive with stable disease without 
additional salvage treatment. Another patient was a 42-year-
old woman who was initially diagnosed with Ann Arbor stage 
IIIA FL in the bilateral supraclavicular fossa, subcarinal, right 
axilla, abdominal, bilateral iliac, and bilateral inguinal lymph 
nodes. She initially received 6 cycles of CHOP chemotherapy 
and interferon-alpha therapy but after 1.5 months, multiple 
residual lesions in the subcarinal, left iliac lymph node chain 
were confirmed on follow-up images. Whole abdomen RT 
of 24 Gy in 16 fractions and mantle field RT of 30 Gy in 20 
fractions were administered. After whole abdomen RT, an 
additional radiation dose up to 34.5 Gy was added to the para-
aortic, pelvic lymph node area. After 6 months, CR at treated 
sites was seen by PET-CT; this response continued until March 
2005. However, outfield relapses in the left neck level II and 
right axilla lymph node area were detected 33 months after 
diagnosis. Additional IFRT was given as salvage treatment, 
specifically to the Waldeyer’s ring to the upper neck lymph 
node at 30.6 Gy in 17 fractions and to the right axilla lymph 
node at 30.6 Gy in 17 fractions with additional radiation in 
the left neck level II lymph node up to 36 Gy. This patient was 
alive without disease 152 months after diagnosis. All patients 
including these relapsed patients are alive and disease-free 
without any treatment-related complications.
In consolidation RT group and salvage RT for progressive 
lesion after chemotherapy group, 100% of CR was also noted 
and there was no relapse or disease-related death. Two 
patients who received consolidation RT after chemotherapy are 
Fig. 2. (A) Overall survival and (B) relapse-free survival from initial diagnosis.
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alive without evidence of disease at 75 and 118 months after 
RT. One patient who received salvage RT for progressive lesion 
is also alive without disease at 23 months after RT. There was 
no treatment-related toxicity after RT in all advanced-stage 
group patients to the last follow-up date.
3. Survival
From initial diagnosis, estimated 5-year RFS was 72% and 10-
year RFS was 60%. In early stage patients, 5-year RFS was 
74.4% and 10-year RFS was 59.5%. In the RT-alone group, 
5-year RFS was 74.5%. In advanced-stage patients, 5-year 
RFS was 66.7% and 10-year RFS was 66.7%. From the date of 
RT start, overall 5-year RFS was 71.8% and 10-year RFS was 
61.6%. In early stage patients, 5-year RFS was 74.4% and 10-
year RFS was 59.5%. In advanced-stage patients, 5-year RFS 
was 62.5% and 10-year RFS was 62.5% (Fig. 2).
From initial diagnosis, 5-year OS was 100% and at 10-year 
OS was 65.2%. OS from the date of RT start was 100% at 5 
years and 54.9% at 10 years. A total of five deaths were noted. 
Disease-specific death occurred in one early stage patient; 
another four died of second malignancies at RT-unrelated 
sites or of underlying disease. For early stage patients, 5-year 
OS was 100% and 10-year OS was 54.3%. For advanced-stage 
patients, both 5-year and 10-year OS were 100%. From the 
date of RT start, for early stage patients, 5-year OS was 100% 
and 10-year OS 41.9%; for advanced-stage patients, 5-year 
and 10-year OS were 100% (Fig. 2). 
Age older than 60 years had a significant impact on both 
RFS and OS in univariate analysis (p = 0.013 and p = 0.056, 
respectively). In patients younger than 60 years old, 5-year 
OS was 100% and 5-year RFS was 57.8%; 10-year OS was 
88.9% and 10-year RFS was 38.5%. Patients older than 60 
years old showed worse prognosis (5-year OS 100% and 
RFS 92.3%; 10-year OS 55.6% and RFS 92.3%). Analysis of 
FLIPI2 scores showed that only RFS between the intermediate 
and high grade groups was significantly different and other 
comparisons were insignificant.
In relapsed patients, no significant relationship was 
demonstrated between treatment characteristics and response 
rates; patients with relapsed disease were very responsive 
to RT. Overall, 50% patients were alive without disease with 
various salvage treatments (median OS from diagnosis, 
95 months), with one disease-related death reported. 
Characteristics of patients who relapsed after RT are in Table 2.
Discussion and Conclusion
In this retrospective study, RT as a primary treatment 
modality (RT alone) for early stage patients or a salvage 
treatment modality for advanced-stage patients resulted 
in excellent treatment outcomes for patient with all stages 
of FL. All patients who received RT as a first-line or second-
line treatment showed CR in the radiation field and excellent 
RFS and OS. We confirmed that FL is a highly radiosensitive 
malignancy and RT could be a treatment option comparable to 
chemotherapy even including rituximab.
In previous studies, FL prognosis and treatment options 
were reported as heterogeneous. Prognostic factors in patients 
with FL are diverse and include age, stage, tumor burden, bone 
marrow involvement, systemic symptoms, performance status, 
serum LDH, hemoglobin, erythrocyte sedimentation rate, and 
β2-microglobulin [16-21]. In 2004, after a large international 
cooperative effort, the FLIPI score was established [20]. 
However, this score was designed before the era of rituximab 
and the initial study cohort does not represent the present 
disease course. Since the FLIPI score has several other 
limitations, the International Follicular Lymphoma Prognostic 
Factor Project group proposed the FLIPI2 score. Results with 
the FLIPI2 score show that β2-microglobulin higher than 
the upper limit of normal, longest diameter of the largest 
involved node longer than 6 cm, bone marrow involvement, 
hemoglobin level lower than 12 g/dL, and age older than 
60 years are independently predictive factors for RFS; these 
factors are proposed for risk group classification [15]. However, 
in our study, only age older than 60 years was a significant 
prognostic factor for all FL stages. FLIPI2 score was not well 
correlated with prognosis. These results might be due to the 
small number of cohort patients.
Many patients are diagnosed with advanced-stage FL 
and 15%–30% present with localized or early stage disease. 
Treatment of early stage FL remains heterogeneous and 
controversial because of a lack of randomized phase III 
trials in this subgroup. According to many retrospective 
studies, RT is considered the standard of care at this stage. 
Alternative treatments include observation, chemotherapy, 
immunotherapy, or both, with or without RT. Previous studies 
on RT outcomes demonstrated excellent local tumor control 
(>90%) and reported RFS in the range of 50% at 10 years and 
approximately 40% at 15 years. OS rates were 60% to 80% at 
10 years and 35% to 45% at 15 years [5,22-24]. Chemotherapy 
alone or combined therapy shows similar response rates 
for early stage FL, but no definitive data from other studies 
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demonstrated an outstanding survival advantage. Despite 
being considered a standard treatment, RT for early stage FL 
is greatly underused in both the United States and Korea. The 
reasons for this underuse could be low accessibility for RT, lack 
of awareness about RT by hematologists, and concerns about 
radiation toxicity. However, FL is known to be highly sensitive 
to radiation and even very low doses may be adequate for 
extended local control. In our retrospective results, the RT-
alone group showed excellent survival outcomes with low 
doses and small fields, comparable to previously reported 
retrospective or prospective outcomes for both RT-alone and 
combined therapy groups. A lower dose approach would make 
RT much safer and easier to administer than chemotherapy 
with comparable treatment outcomes. Because of these 
advantages, RT should be considered more frequently for early 
stage FL.
For advanced-stage FL, the addition of rituximab to standard 
chemotherapy is recommended for first-line treatment in 
symptomatic patients. Both expectant management (watchful 
waiting) and rituximab monotherapy are recommended 
for patients without symptoms or with low tumor burden 
according to several international guidelines. The benefits 
of rituximab have been shown for rituximab followed 
by rituximab maintenance or in combination with other 
chemotherapy regimens. Rituximab followed by rituximab 
maintenance has overall response rates of 76% and a median 
RFS of 34 months in symptomatic patients [25]. Rituximab 
with other chemotherapy improves both response rates and OS 
rates according to four randomized studies showing response 
rates of 81% to 96% and median remission durations of 27 
to 66 months [8,10,12,26]. R-CHOP was the most effective 
treatment option with better response rates (91%–93%), RFS 
(3-year, 68%; median, 40.9 months) and lower toxicity than 
other combination options [27-29]. 
Limited studies are available on RT as a first-line treatment 
for advanced-stage FL. Studies that showed survival benefits 
were performed with palliative intent for symptomatic or 
some bulky diseases. In the rituximab era, much fewer reports 
on RT alone have been published due to the outstanding 
response rates of rituximab. Thus, RT is currently recommended 
only for patients with symptomatic disease as a palliative 
treatment option. Response rates range from 75% to 92% 
and CR rates range from 36% to 61% for advanced-stage FL. 
In several previous retrospective studies on central lymphatic 
irradiation including mantle field, whole abdomen, and pelvis 
fields, including in patients with stage III disease, 5-year RFS 
rates fell to about 50% in most series [23,30]. McClanahan 
et al. [31] showed the benefit of consolidation IFRT after 
immunochemotherapy including rituximab was evaluated 
in patients in the HD2000 prospective trial. Although no 
significant difference was noted between exposure to IFRT 
and likelihood of relapse (p = 0.751) or at a specific location 
(p = 0.66), 6-year RFS was 52% and 6-year OS was 80% 
after IFRT; RFS was 48% and OS was 73% without IFRT. In 
our study, although only small numbers of advanced-stage 
patients were included, 5-year RFS from initial diagnosis was 
66.7% and 5-year OS from initial diagnosis was 100%, which 
were similar to previous reports. We found no differences in 
treatment outcomes for RT for bulky diseases. Asserting that 
RT alone as a first-line treatment option for advanced-stage 
patients might not be feasible, because of the small number of 
reports showing benefits in heterogeneous patient groups in 
the rituximab era. However, RT can be a reasonable treatment 
option with excellent response rates and very low toxicity for 
relapsed or refractory patients. Treatment options for relapsed 
FL vary and include chemotherapy with or without rituximab, 
rituximab monotherapy, local RT, and radioimmunotherapy. 
Previous treatment history and duration of response should 
be considered in selecting the most appropriate salvage 
treatment. Until now, CHOP chemotherapy or rituximab 
have also been reasonable options, but they have not been 
evaluated prospectively and have marginal utility. Our results 
demonstrated that RT was a very effective salvage treatment 
option for relapsed patients.
Our study was limited, first because of the retrospective 
study design and small sample size. However, few studies have 
reported RT outcomes for FL because of the low incidence 
in Korea and treatment options other than RT. Especially 
for patients with advanced-stage disease, most institutions 
regard chemotherapy including rituximab as a first-line 
treatment and RT experiences have not been widely shared 
between institutions. Thus, our report is valuable because it 
addresses this situation. Second, our study cohort included 
only patients who were referred to our radiation oncology 
department. In particular, the advanced-stage group had a 
small number of patients with varying disease status. Although 
physicians were concerned about radiation toxicity in selecting 
treatment modalities, all patients tolerated RT without serious 
complications. Because recent recommendations about RT 
dose and fields have become much lower and smaller (IFRT, 
ISRT), RT is expected to be more comfortable for patients 
without compromising treatment outcome. Some good 
responders in our advanced-stage group were older than 50 
year-old or had severe disease status despite several cycles of 
Seo Hee Choi, et al
318 www.e-roj.org http://dx.doi.org/10.3857/roj.2015.33.4.310
chemotherapy. Thus, we concluded from our results that RT 
was highly effective regardless of the patient’s performance 
status, disease severity, or disease sites.
In conclusion, our experience showed that RT can be a 
highly effective treatment modality as a primary or salvage 
treatment option for management of all stages of FL. In Korea, 
very few studies have assessed use of RT for non-Hodgkin 
lymphoma, especially FL. Our findings will therefore be 
valuable for selecting the most appropriate treatment options 
for FL. RT can be more widely recommended for patients with 
all stages of FL, with or without chemotherapy.
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